SCHEMBL19900144

SCHEMBL19900144

Cc1nc(N2CCC2)nc(OC2CCC2)c1O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.36
▸ PDE10A Q9Y233 1/20 0.34
▸ FFAR4 Q5NUL3 2/20 0.33
▸ HRH4 Q9H3N8 1/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ HTT P42858 1/20 0.33
▸ RECQL P46063 1/20 0.33
▸ ATM Q13315 1/20 0.33
▸ KCNQ3 O43525 6/20 0.32
▸ KCNQ2 O43526 6/20 0.32
▸ POLB P06746 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ GPR119 Q8TDV5 2/20 0.31
▸ KDM4E B2RXH2 2/20 0.31
▸ HSD17B10 Q99714 2/20 0.31
▸ SCD O00767 1/20 0.31
▸ USP2 O75604 1/20 0.31
▸ HPGD P15428 1/20 0.31
▸ NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29732895 0.82 ALDH1A1 (0.36) ALDH1A1PDE10AFFAR4HRH4MEN1
SCHEMBL19900326 0.82 ALDH1A1 (0.36) ALDH1A1PDE10AFFAR4HRH4MEN1
SCHEMBL19899806 0.76 LRRK2 (0.36) FFAR4
SCHEMBL29732959 0.76 CHRM1 (0.30) —
SCHEMBL19900340 0.76 CHRM1 (0.30) —
SCHEMBL19900199 0.73 CHRM3 (0.36) ALDH1A1PDE10AFFAR4HRH4SCD
SCHEMBL29732718 0.73 CHRM3 (0.36) ALDH1A1PDE10AFFAR4HRH4SCD
SCHEMBL18005522 0.73 MEN1 (0.32) MEN1KMT2AHTTKCNQ3KCNQ2
SCHEMBL19900284 0.71 ALDH1A1 (0.51) ALDH1A1HRH4MEN1KMT2AHTT
SCHEMBL18005303 0.70 MAPT (0.46) POLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12595250-B2 Substituted pyrimidine compounds as multifunctional radical quenchers and their uses ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2026-04-07 — — US disclosed
US-20220324841-A1 THERAPEUTIC COMPOUNDS ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2022-10-13 — — US disclosed
US-11390605-B2 Substituted pyrimidine compounds as multifunctional radical quenchers and their uses ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2022-07-19 — — US disclosed
US-20210276979-A1 THERAPEUTIC COMPOUNDS ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2021-09-09 — — US disclosed
US-20210276979-A1 THERAPEUTIC COMPOUNDS ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2021-09-09 — — US disclosed
WO-2018039077-A1 THERAPEUTIC COMPOUNDS ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2018-03-01 — — WO disclosed
WO-2018039077-A1 THERAPEUTIC COMPOUNDS ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2018-03-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12595250-B2 Substituted pyrimidine compounds as multifunctional radical quenchers and their uses GSR, UQCRC1, TXNRD2 ALDH1A1 573/4885PDE10A 2815/4885FFAR4 1247/4885
US-20220324841-A1 THERAPEUTIC COMPOUNDS CFTR, F12, FURIN ALDH1A1 674/4885PDE10A 991/4885FFAR4 4346/4885
US-20210276979-A1 THERAPEUTIC COMPOUNDS CFTR, F12, FURIN ALDH1A1 674/4885PDE10A 991/4885FFAR4 4346/4885
US-11390605-B2 Substituted pyrimidine compounds as multifunctional radical quenchers and their uses DPYD, TYMP, NUDT1 ALDH1A1 599/4885PDE10A 1997/4885FFAR4 3407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback